Analysis of the stratum corneum structure in the patients taking erlotinib -Towards the investigation of the mechanism of skin rash by the development of erlotinib administration

Not Applicable

• Conditions: on-small cell lung cancer

• Registration Number: JPRN-UMIN000020675
• Lead Sponsor: Department of clinical pharmaceutics, School of Pharmaceutical Sciences, Univercity of Shizuoka

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2016-01-21
• Study Completion: 2021-02-15
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Not provided

Exclusion Criteria

1. Patients with a history of allergy for a component of erlotinib 2. Patients with a history of EGFR inhibitor treatment before erlotinib administration (except for the patients with gefitinib treatment before erlotinib administration) 3. Patients with a history of serious drug allergy 4. Patients with other serious complications 5. Patients with a history of serious drug allergy 6. Patients who are in pregnancy or intend to get pregnant 7. Patients who are considered to be inappropriate in enrollment of this trial by attending physicians 8. Patients with orally steroid treatment

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Transepidermal water loss(TEWL), Analysis of ceramide components, lateral structure of stratum corneum